16 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
setrusumab, alvelestat, etigilimab, acumapimod and leflutrozole; building our intellectual property portfolio; developing our supply chain; planning our … by the current or anticipated impact of supply chain disruptions, labor shortages, fluctuations in currency exchange rates, changes in interest rates, trade
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
2 Nov 21
Current report (foreign)
4:16pm
required for the Company’s ongoing development activities;
Supply chain interruptions; or
Diversion of CMO activities and raw materials to COVID-19
F-3/A
MREO
Mereo Biopharma Group Plc
27 Sep 21
Shelf registration (foreign) (amended)
4:18pm
authorities in relation to approvals, amendments or other regulatory engagements required for our ongoing development activities;
Supply chain
F-3/A
MREO
Mereo Biopharma Group Plc
7 Sep 21
Shelf registration (foreign) (amended)
4:06pm
engagements required for our ongoing development activities;
Supply chain interruptions; or
Diversion of CMO activities and raw materials to COVID-19
F-3
ohhu5b4
5 Aug 21
Shelf registration (foreign)
4:33pm
6-K
3gk5cudqxr1vll5n
28 Apr 20
Current report (foreign)
4:10pm
F-1/A
k9dzmz ln3o7bpvamth
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
hmil 705z3
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
20-F
dtjwoqz76 8og4cp2a
29 Apr 19
Annual report (foreign)
4:59pm
424B3
2nimc5 y3yxh5ujg
20 Mar 19
Prospectus supplement
4:58pm
F-4/A
rhutaz22gvrmdh 0q
15 Mar 19
Registration of securities (foreign) (amended)
5:08pm
F-4
7sgooy
25 Jan 19
Registration of securities (foreign)
12:00am
- Prev
- 1
- Next